Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
复制标题
DOI：
10.1111/dom.13920
复制
发表时间：
2020-04-01
影响因子：
5.8
通讯作者：
Neal, Bruce
中科院分区：
文献类型：
--
作者：
Ohkuma, Toshiaki;Van Gaal, Luc;Neal, Bruce
钠葡萄糖协同转运蛋白2（SGLT 2）抑制剂可降低几种心血管风险因素，包括血糖、血压、蛋白尿和体重。长期治疗可降低心血管和肾脏事件的风险。这项事后分析的目的是确定卡格列净治疗与安慰剂相比对与体重指数（BMI）相关的临床结果的影响。材料和方法CANVAS计划将10142名2型糖尿病参与者随机分配至卡格列净或安慰剂组。这些分析检验了在按基线BMI定义的三个组中，不同BMI水平的卡格列净治疗效果在心血管、肾脏、安全性和体重结局方面的一致性：
Aims Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce several cardiovascular risk factors, including plasma glucose, blood pressure, albuminuria and body weight. Long-term treatment lowers risks of cardiovascular and renal events. The objective of this post hoc analysis was to determine the effects of canagliflozin treatment versus placebo on clinical outcomes in relation to body mass index (BMI).Materials and methods The CANVAS Program randomized 10 142 participants with type 2 diabetes to canagliflozin or placebo. These analyses tested the consistency of canagliflozin treatment effects across BMI levels for cardiovascular, renal, safety and body weight outcomes in three groups defined by baseline BMI: